Abstract
Although cutaneous angiosarcoma (cAS) has one of the worst prognoses among malignant skin tumors, few effective drug options for secondary treatment have been discovered to date because of the limited number of cases. Therefore, this study was aimed at determining pazopanib’s potential as a new cAS treatment option. We retrospectively evaluated five patients with taxane-resistant unresectable cAS treated with pazopanib at a university hospital. Their characteristics and treatment outcomes were retrieved from their records. Progression-free survival (PFS), overall survival (OS), disease progression, and toxicity were evaluated; furthermore, the response to pazopanib was assessed in relation to the expression of vascular endothelial growth factor receptor 2 (VEGFR-2). The median PFS from the time of pazopanib initiation was 94 days. Two patients showed partial response, two showed stable disease, and one had progressive disease in the case of the best overall response. VEGFR-2 expression was positive in all cases, and patients with high expression had improved median OS compared to that in those with low expression. VEGFR-2 expression was correlated with a longer OS. The most common toxicities were hypertension and anorexia followed by myelosuppression. This is the largest case series reported wherein pazopanib was used for taxane-resistant cAS. Although the cytoreductive effect and survival benefits were not significant in this small sample, we consider pazopanib a valid treatment option for preserving patients’ quality of life. Our results suggest pazopanib treatment slows the progression of disease and stabilizes it in patients with taxane-resistant cAS.
References
Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61:170–6.
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046–57.
Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98:1716–26.
Fujisawa Y, Yoshino K, Kadono T, Miyagawa T, Nakamura Y, Fujimoto M. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br J Dermatol. 2014;171:1493–500.
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
National Institutes of Health National Cancer Institute. Adverse Events Version 4.0 (CTCAE) (v4.02: 2009 September 15). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf. Accessed 11 May 2016.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.
Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44:2433–6.
Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74–81.
Yonemori K, Tsuta K, Ando M, et al. Contrasting prognostic implications of platelet-derived growth factor receptor-b and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. Ann Surg Oncol. 2011;18:2841–50.
Kitamura S, Hata H, Imafuku K, Haga N, Homma E, Shimizu H. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma. Clin Exp Dermatol. 2015;40:931–3.
Fujiwara S, Nagai H, Nakamachi Y, Kawano S, Nishigori C. Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib. Eur J Dermatol. 2015;25:71–3.
Fujita M, Endo Y, Fujisawa A, Tanioka M, Kabashima K, Miyachi Y. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma. Eur J Dermatol. 2014;24:267–8.
Tomita H, Koike Y, Asai M, et al. Angiosarcoma of the scalp successfully treated with pazopanib. J Am Acad Dermatol. 2014;70:19–21.
Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616–27.
Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–21.
Acknowledgments
This work was partly supported by the National Cancer Center Research and Development Fund (Grant Number 26-A-4). The funder played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author contributions
Dai Ogata, Kohei Oashi, Naoya Yamazki, and Tetsuya Tsuchida contributed to manuscript drafting. Dai Ogata, Hiroto Yanagisawa, and Kenji Suzuki contributed to data collection. Dai Ogata analyzed the data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Ogata, D., Yanagisawa, H., Suzuki, K. et al. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Med Oncol 33, 116 (2016). https://doi.org/10.1007/s12032-016-0831-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-016-0831-z